Press "Enter" to skip to content

FDA warns repackers distributing pharmaceutical ingredients, including opioids, for putting consumers at risk with significant violations of manufacturing quality standards

FDA has issued warning letters to three repackers of active pharmaceutical ingredients (API) for significant violations of current good manufacturing practice (CGMP) requirements

Original source:

Also Read:   Medtronic Recalls SynchroMed II Implantable Drug Infusion Pump Due to the Potential Presence of Foreign Particles Inside the Pump Motor Assembly Which May Lead to a Pump Motor Stall